Adalvo is delighted to announce a significant achievement for January 2024, securing a total of 69 Marketing Authorisation Approvals. This success spans across 18 countries, in collaboration with 12 esteemed strategic partners.
During this period, we have also submitted a total of 101 Marketing Authorisation applications, showcasing Adalvo’s commitment to setting a regulatory standard.
The approved products encompass a diverse array of therapeutic areas, highlighting the depth of Adalvo's pharmaceutical portfolio.
Our team's collective expertise, diligence, and commitment have been pivotal in reaching this significant milestone.
We would also like to extend our gratitude to all our partners and anticipate building upon this momentum throughout the year.
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - North and South Europe & LATAM
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil & MENA
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!